Siemens Healthineers recently added
non-small cell lung cancer support to its AI Pathway Companion. Currently
supported pathways are non-small cell lung and prostate cancer.
Siemens first presented its AI Pathway Companion at the 2018 Annual Meeting of the Radiological Society of North America in Chicago. The system delivers artificial intelligence (AI)-supported clinical decision support (CDS) for physicians making diagnostic and treatment decisions along specified clinical pathways. It helps physician teams better manage patient care and case reviews by organising patient information within a single dashboard, providing quality checks on data completeness, and enabling relevant patient-specific notations documentation. It updates the patient’s clinical status to the physician team and advises on the next steps according to established guidelines. As information is shared across interdepartmental care teams, this facilitates inter-department collaboration.
Siemens Healthineers intends to enlarge the number of captured disease parameters in the clinical pathway, increasing the relevant data points for determining the next steps in care. The company plans to partner with healthcare institutions that wish to optimise the AI-Pathway Companion to their routine clinical service and lung cancer workflow.
University of Missouri Health Care is one partner institution that recently incorporated the AI-Pathway Companion for Prostate Cancer. To incorporate the such a system into the organisational workflow, the advice below is offered:
1. Let the clinicians take lead and champion the benefits of the CDS system for patients and the provider.
2. Partner with a CDS solution provider that can provide long-term support.
Image Source: Siemens Healthineers